
Novavax (NVAX) Stock Forecast & Price Target
Novavax (NVAX) Analyst Ratings
Bulls say
Novavax is well-positioned for growth due to its unique vaccine technology and impressive pipeline of high-value assets. The positive outlook for Novavax is further supported by its partnerships with other companies to drive value creation and its potential to address both known and emerging diseases. The recent survey results project a declining COVID-19 vaccine market in the US, which could lead to increased demand for Novavax's vaccine candidates. Furthermore, the positive results from the Sanofi COMPARE study and the potential differentiated tolerability profile of Nuvaxovid may give Novavax a competitive edge in the market.
Bears say
Novavax is a biotechnology company with several potential opportunities, including a commercial partnership with Sanofi that could provide mid-term growth, and internal pipeline candidates that could add value in the long term. However, there are significant challenges, such as the uncertain outlook for COVID-19 vaccines and the commercial viability of a flu/COVID-19 combo vaccine, which could impede the company's success. Additionally, with competition from established vaccine manufacturers and the company's emphasis on its Matrix-M adjuvant, which has yet to show significant impact, there are concerns about the company's ability to gain market share and generate sustainable profits in the near term.
This aggregate rating is based on analysts' research of Novavax and is not a guaranteed prediction by Public.com or investment advice.
Novavax (NVAX) Analyst Forecast & Price Prediction
Start investing in Novavax (NVAX)
Order type
Buy in
Order amount
Est. shares
0 shares